Exactly and all these basher say the money is a

Exactly and all these basher say the money is a problem. I see it all the time with these bio stocks. I just saw one today get a 90 million dollar licensing deal today with up front money. The company had one indication I believe. Imagine if we had several deals done at once ?

Now I don’t want to get my hopes up because I think we are still a few years off from double digits. Maybe…

However, I’ve seen stranger things. If we partner with a bunch of companies all bets are off as to where this thing can go and how long it will take.

People have to remember this is not a normal company. It’s a platform drug. Not just one with 2-3 indications. We are talking dozens of indications.

Jazz’s market cap isn’t even high. Cytodny could make GILDs market cap look like a joke and even J&Js if this matures the way it should. I just hope we don’t do some NASH partnership deal. 4 years fly by and we get some offer after the phase 3 results for 10 dollars. That seems to be the trends for these companies. The buyouts are low. IMMU had a decent buyout I had my eyes on it at 10 and then next thing I know it was at 80. Still I’d rather see this grow into a major company.

I’m all set with 5 dollars even though I’ll be well into six figures with this stock at that point.

I guess we will have to wait and see.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009

(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech

Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025

FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy


— Jeremiah 51:36